STANFORD UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1885-11-11

Employees: 10K

Market Cap: -

Website: http://www.stanford.edu

Clinical Trials

Identification of Key Blood Molecular Markers for Immunotherapy

Terminated

Conditions: Adenocarcinoma
Neoplasms
Squamous Cell Carcinoma

First Posted Date: 2007-07-26

Last Posted Date: 2019-04-18

Lead Sponsor: Stanford University

Target Recruit Count: 191

Registration Number: NCT00507702

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Imatinib in Systemic Sclerosis

Phase 1

Completed

Conditions: Scleroderma, Systemic

Interventions: Drug: Imatinib mesylate

First Posted Date: 2007-07-25

Last Posted Date: 2018-08-13

Lead Sponsor: Stanford University

Target Recruit Count: 9

Registration Number: NCT00506831

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Pain Study of Rectus Muscle Closure at Cesarean Delivery

Not Applicable

Completed

Conditions: Pain

Interventions: Procedure: Rectus closure

First Posted Date: 2007-07-23

Last Posted Date: 2017-11-06

Lead Sponsor: Stanford University

Target Recruit Count: 63

Registration Number: NCT00505362

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Spanish Diabetes Self-Management Program

Not Applicable

Completed

Conditions: Type 2 Diabetes

Interventions: Behavioral: Spanish Diabetes Self-Management Program

First Posted Date: 2007-07-04

Last Posted Date: 2016-04-19

Lead Sponsor: Stanford University

Target Recruit Count: 567

Registration Number: NCT00496145

Locations: 🇺🇸
Stanford Patient Education Research Center, Palo Alto, California, United States

Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy

Phase 2

Terminated

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: Bexxar (tositumomab)
Procedure: External beam radiotherapy (XRT)
Drug: Potassium Iodide (KI)

First Posted Date: 2007-06-22

Last Posted Date: 2017-03-29

Lead Sponsor: Stanford University

Target Recruit Count: 8

Registration Number: NCT00490490

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Assessment and Rehabilitation of Cognitive Impairments in Pediatric Survivors of Cancer

Completed

Conditions: Neoplasms

First Posted Date: 2007-06-22

Last Posted Date: 2015-05-21

Lead Sponsor: Stanford University

Target Recruit Count: 72

Registration Number: NCT00490334

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Indomethacin Versus Nifedipine for Preterm Labor Tocolysis

Phase 1

Completed

Conditions: Obstetric Labor, Premature

Interventions: Drug: Indomethacin
Drug: Nifedipine

First Posted Date: 2007-06-15

Last Posted Date: 2018-10-01

Lead Sponsor: Stanford University

Target Recruit Count: 29

Registration Number: NCT00486824

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Phase 2

Terminated

Conditions: Lymphoma, B-cell
Lymphoma, Non-Hodgkin
Diffuse Large B-cell Lymphoma (DLBCL)
Malignant Lymphoma, Non-Hodgkin

Interventions: Procedure: Autologous hematopoietic stem cell transplantation (auto-HSCT)
Procedure: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Procedure: Total lymphoid irradiation (TLI)
Drug: Rituximab
Drug: Carmustine
Drug: Etoposide
Drug: Filgrastim
Drug: Anti-thymocyte globulin (ATG)
Drug: Cyclosporine
Drug: Mycophenolate mofetil (MMF)
Drug: Cyclophosphamide
Drug: Acetaminophen
Drug: Diphenhydramine
Drug: Hydrocortisone
Drug: Methylprednisolone

First Posted Date: 2007-06-04

Last Posted Date: 2018-05-14

Lead Sponsor: Stanford University

Target Recruit Count: 3

Registration Number: NCT00482053

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Vandetanib
Drug: Anastrozole

First Posted Date: 2007-06-04

Last Posted Date: 2017-02-07

Lead Sponsor: Stanford University

Target Recruit Count: 1

Registration Number: NCT00481845

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Calcitriol or Placebo in Men for Prostate Cancer Active Surveillance

Not Applicable

Withdrawn

Conditions: Prostate Cancer
Prostatic Neoplasms

First Posted Date: 2007-06-04

Last Posted Date: 2022-03-03

Lead Sponsor: Stanford University

Registration Number: NCT00482157

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy